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JECTIVES: To estimate the socioeconomic impact of cil-
ostazol with concern to the prevention of cerebral infarc-
tion recurrences in Japan. METHODS: A Markov model
was constructed to estimate the costs and the number of
recurrences of cerebral infarction over a 5-year period for
50-year-old males. Annual average rates of cerebral inf-
arction recurrences were derived from the RCT. QALYs
were not considered due to a lack of utility data in Japan.
Direct and indirect costs were calculated based on pub-
lished data. Costs and the numbers of recurrences were
discounted at 3% per annum. RESULTS: The cumulative
number of recurrences of cerebral infarction over 5 years
per 1000 people was 95 for the cilostazol group, and 272
for the no treatment group. The 5 year cumulative costs
per person were 5,260,108 yen for the cilostazol group, and
11,374,638 yen for the no treatment group. Sensitivity anal-
yses confirmed the robustness of these results. CONCLU-
SIONS: This study suggests that cilostazol is a valid form
of treatment for the prevention of cerebral infarction re-
currences in Japan from a socioeconomic standpoint.
PCD8
A MODEL COMPARING NITROGLYCERIN 
FORMULATIONS FOR ACUTE ANGINA 
EPISODES: ASSESSING THE ECONOMIC ISSUES
Bell CF, Semroc GN, Stephens JM, Klingman D, Dever MT
PAREXEL International, Outcomes Research Group, 
Alexandria, VA, USA
Nitroglycerin (NTG) therapy, with its rapid onset of ac-
tion, is ideal for treating patients with acute episodes of
angina. However, NTG therapy is often limited by stor-
age and stability issues. OBJECTIVE: To develop an eco-
nomic model comparing per-patient costs, drug wastage,
and potency of lingual NTG spray versus sublingual
NTG tablets in patients with chronic stable angina.
METHODS: Major inputs to the model included number
of episodes of acute angina per week, duration of ther-
apy, prescription costs, number of doses per episode, ini-
tial medication potency, and rate of decline in potency.
Outcomes were assessed according to patient severity
(mild, moderate, or severe), defined by the number of
acute episodes of angina per week. Data were gathered
using published clinical and economic literature and ex-
pert opinion. RESULTS: Over a two-year period, total
drug acquisition cost and drug wastage for lingual NTG
spray were lower than the sublingual NTG tablet, regard-
less of severity. Differences in total drug acquisition costs
and drug wastage were greatest among mild angina pa-
tients (defined as one episode per week). For these pa-
tients, total two-year drug acquisition cost for sublingual
NTG tablets was more than three times that of lingual
NTG spray; drug wastage was estimated to be 85% of
the total number of sublingual NTG tablets provided.
Sublingual NTG tablet stability was considered the key
cost driver, at all levels of severity. CONCLUSION: This
analysis illustrates the impact of NTG drug wastage and
stability on the costs of treating patients with angina.
Further analyses addressing these issues should be con-
ducted to better inform health care audiences on how best
to cost-effectively treat patients with angina.
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OBJECTIVES: The purpose of our analysis was to quantify
the cost-effectiveness of angiotensin-converting-enzyme in-
hibitor treatment with ramipril versus conventional treat-
ment in hypertensive patients with nephropathy from the
perspective of a German third-party payer. METHODS:
This retrospective analysis used the cost-effectiveness ra-
tio additional cost for ramipril per patient-year of
chronic dialysis avoided (PYCDA) as the target variable
and was based on a modelling approach. Costs for rami-
pril, chronic dialysis and kidney transplantation were
taken from published data. PYCDA after 3 years’ treat-
ment were obtained from the cumulative incidence curves
of end-stage renal disease (ESRD) of the original patient
data from stratum 2 in the clinical trial, the Ramipril Ef-
ficacy in Nephropathy study, and were corrected for
mortality following chronic dialysis. Costs and effective-
ness were discounted by 5% annually. RESULTS: The
base-case analysis revealed net savings of about 76,700
DM per PYCDA after 1 year treatment (net savings of
295,905 DM and 3.9 PYCDA per 100 patients each)
reaching net savings of about 81,900 DM per PYCDA af-
ter 3 years. In the sensitivity analysis (i) analysis of ex-
tremes (ii) impact analysis, and (iii) Monte Carlo simula-
tion were applied. In addition, PYCDA were quantified
according to the Weibull method. The model turned out
to be robust. There were net savings per PYCDA
through ramipril treatment after 1, 2 and 3 years with a
broad variance of between 53,000 DM and 104,000 DM
after 3 years. CONCLUSIONS: Given the considerable
societal and economic impact of ESRD on the healthcare
system, the clinical and economic benefits of administer-
ing ramipril to hypertensive patients with nephropathy
show an enormous saving potential.
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We previously reported that the market for HMG-CoA-
reductase inhibitors (“statins”) in the US was segmented
into lower-priced/less-effective and higher-priced/more-effec-
tive products. The introduction of new higher doses of ceriv-
